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AbsTrACT
background/aims intestinal permeability with systemic 
distribution of bacterial products are central in the 
immunopathogenesis of alcoholic liver disease (alD), yet 
links with intestinal immunity remain elusive. Mucosa-
associated invariant t cells (Mait) are found in liver, 
blood and intestinal mucosa and are a key component of 
antibacterial host defences. their role in alD is unknown.
Methods/design We analysed frequency, phenotype, 
transcriptional regulation and function of blood Mait 
cells in severe alcoholic hepatitis (SaH), alcohol-related 
cirrhosis (arc) and healthy controls (Hc). We also 
examined direct impact of ethanol, bacterial products 
from faecal extracts and antigenic hyperstimulation 
on Mait cell functionality. Presence of Mait cells in 
colon and liver was assessed by quantitative Pcr and 
immunohistochemistry/gene expression respectively.
results in arc and SaH, blood Mait cells were 
dramatically depleted, hyperactivated and displayed 
defective antibacterial cytokine/cytotoxic responses. 
these correlated with suppression of lineage-specific 
transcription factors and hyperexpression of homing 
receptors in the liver with intrahepatic preservation of 
Mait cells in alD. these alterations were stronger in 
SaH, where surrogate markers of bacterial infection 
and microbial translocation were higher than arc. 
ethanol exposure in vitro, in vivo alcohol withdrawal and 
treatment with Escherichia coli had no effect on Mait 
cell frequencies, whereas exposure to faecal bacteria/
antigens induced functional impairments comparable 
with blood Mait cells from alD and significant Mait 
cell depletion, which was not observed in other t cell 
compartments.
Conclusions in alD, the antibacterial potency of Mait 
cells is compromised as a consequence of contact with 
microbial products and microbiota, suggesting that the 
’leaky’ gut observed in alD drives Mait cell dysfunction 
and susceptibility to infection in these patients.
InTroduCTIon
Alcohol-related liver cirrhosis (ARC) induces 
a state of profound immunodeficiency, known 
as cirrhosis-associated immunodeficiency 
syndrome (CAIDS).1–3 When patients with 
alcohol-related liver disease (ALD) present with 
severe alcoholic hepatitis (SAH), the susceptibility 
to bacterial infection is further heightened, and 
infection is observed in nearly 50% of cases in the 
short term.4 We recently illustrated widespread 
impairment of antibacterial adaptive T cells in SAH 
and showed restoration of function with immune 
checkpoint-receptor inhibition.5 Interestingly, we 
did not observe adaptive T cell dysfunctions in 
ARC,5 suggesting that alternate mechanisms drive 
immunoparesis in these patients. Infection in ARC 
precipitates severe complications including septic 
shock, acute-on-chronic liver failure and multi-
organ failure.2 3 Therefore, it is imperative that we 
delineate common and divergent immune pathways 
in ARC and SAH to develop specific and targeted 
immunotherapeutic strategies to reconstitute the 
host immunity, rather than the continued use of 
antibiotics in an era of multidrug resistance.6 
MAIT cells are innate-like CD161-positive antibac-
terial T cells considered key for the immune control 
of gut microbiota, bacterial infection and inflamma-
tory diseases.7–11 Initially characterised in the intes-
tinal mucosa, they are now known to be the most 
predominant population of intrahepatic T cells and 
appear in high frequencies in the peripheral blood 
physiologically.8 12–14 MAIT cells have a semi-invariant 
T cell receptor, containing the Vα7.2-Jα33 chain and 
a diverse Vβ-chain pool.11 They recognise riboflavin 
metabolites of bacterial/fungal origin presented via 
the major histocompatibility complex (MHC)-related 
molecule 1 (MR1),15 which is inducible upon bacterial 
infection16 or IFNγ stimulation17 and expressed on 
various cells, including B cells and monocyte.16 Mature 
MAIT cells are predominantly CD8 single-posi-
tive,15 18 express the immunoenzyme CD26, the inter-
leukin (IL)-7/IL-18 receptors and respond to both T 
cell receptor (TCR)-dependent and TCR-indepen-
dent stimulation.17 19 Activated MAIT cells perform 
antibacterial functions by secreting cytokines (IFNγ/
TNFα/IL-17) and killing MR1-positive infected 
cells.8 11 20–24
Given that MAIT cells defend the host at key loca-
tions associated with alcohol-induced liver injury, 
namely the gut and the liver, we hypothesised that 
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they may play an important role in the immunopathogenesis of 
ALD.
MATerIAls And MeThods
subjects and study design
The study was performed conforming to the Declaration of 
Helsinki, with full informed patients’ consent and individual 
ethical approval from all recruiting centres (online supplemen-
tary methods).
 A. MAIT cell phenotype and function were primarily assessed 
on the following three cohorts:
1. SAH (n=13): with Maddrey’s discriminant function ≥32,25 
excluding patients receiving immunosuppressants prior to/at 
the time of sampling.
2. ARC (n=9): excess alcohol drinkers (>80 g/day/male, >60 g/
day/female) with compensated disease (Child-Pugh A/B) seen 
as outpatients, excluding patients with >4 weeks abstinence, 
cancer, GI bleeding, untreated sepsis or immunomodulatory 
treatments.
3. Healthy controls (HCs; n=13): non-smoking healthy 
volunteers.
In addition, long-term excess alcohol users undergoing moni-
tored short-term alcohol withdrawal (n=35, paired) were 
tested at baseline (still drinking) and after 2–5 days of absti-
nence. Subjects were recruited from the Salvation Army alcohol 
rehabilitation centre based on Drug and Alcohol Action Team 
(DAAT) referrals, with exclusion of patients with documented 
severe mental disorders (DAAT documents, Salvation Army 
screening and nursing team interviews) and/or unable to give 
informed consent. Of these 35 patients, five had liver stiffness 
(measured by FibroScan ‘E’ parameter) above threshold for 
cirrhosis (≥12), while 20 had liver stiffness <7.
Bacterial infection was defined as previously shown.5
B. To investigate the impact of faecal extracts on MAIT cells: 
stool samples were collected from 27 patients with ALD (SAH: 
n=7; ARC: n=20) and 12 HCs.
C. To measure MAIT cell frequencies in colon and liver tissue: 
colon pinch biopsies were obtained from 11 ARC and 10 HCs 
colon resections; liver biopsies were obtained from explanted 
livers of five ARC and five healthy liver donors.
Table 1 summarises all patients’ characteristics.
Isolation of peripheral blood mononuclear cells (PbMC)
PBMC were isolated by density gradient centrifugation (Lymph-
oprep, Alere, Stockport, UK) and cryopreserved in 10% DMSO 
(Sigma-Aldrich, Gillingham, UK) as previously described.5 26
Plasma endotoxin and d-lactate
Surrogate markers of bacterial infection and intestinal transloca-
tion27 were measured with the Limulus-amebocyte-lysate assay 
significance of this study
What is already known on this subject?
 ► One of the major and most common complications that patients with alcohol-related liver disease (ALD) face is an increased 
susceptibility to infection, which can lead to worsening of liver disease and multiorgan failure. Indeed, the inability to contend with 
bacterial infection is associated with a four-fold increase in mortality, and once the infection is established 30% of these patients 
will die within 1 month and a further 30% by 1 year. To date, we have limited understanding regarding the processes that mediate 
this immune impairment. Recently, a new subset of innate T cells, known as mucosa-associated invariant T cells (MAIT), have been 
described as a key component in the arsenal of antibacterial host defences. These are unconventional T cells that respond to bacteria-
derived metabolites and are found in large numbers in the liver, intestinal mucosa and peripheral blood. They represent a fundamental 
sentinel system for the homeostatic control of the gut flora and exert essential roles for the control of bacterial infections. Given that 
these cells defend the host at key locations associated with alcoholic liver disease, such as the gut and the liver, it is likely that they 
are intimately involved in the susceptibility to infection observed in patients with ALD. This study is the first report comprehensively 
describing their role in the defective antibacterial immunity in ALD, which was previously unknown.
What are the new findings?
 ► A broad spectrum of dramatic quantitative and functional impairments of blood MAIT cells exist in patients with alcohol-related 
cirrhosis, which is exacerbated in those with severe alcoholic hepatitis possibly signifying an association with disease severity.
 ► The majority of blood MAIT cells in patients with ALD are deleted and the remaining population exists in a state of ‘poised’ activation, 
displaying increased expression of activation markers, but lack of lineage-specific transcription factors and significantly compromised 
antibacterial cytokine and cytotoxic responses.
 ► Loss of gut integrity and the increased translocation of gut bacteria, bacterial antigens and metabolic products drive selective MAIT cell 
depletion and dysfunction resulting in highly compromised antibacterial defence systemically.
 ► Intrahepatic MAIT cells in ALD are numerically preserved with preferential portal accumulation, despite a significant deficit in blood 
MAIT cell frequencies, suggesting a key role as biliary firewall protecting the epithelial lining from translocated bacteria.
how might it impact on clinical practice in the foreseeable future?
 ► The most common cause of death in patients with alcohol-related liver cirrhosis is the development of serious bacterial infections 
as a consequence of impaired host immune defences. Current guidelines recommend intensive and early antibiotic therapy in these 
patients. However, this has led to the increasing emergence of multidrug-resistant bacteria. These infections are associated with a 
higher incidence of septic shock and/or rapid deterioration of liver function and death. As such, there is a pressing need to explore 
new paradigms for anti-infective therapy, and we believe that host-directed immunomodulatory therapies are a promising approach. 
The findings from this report highlight MAIT cells as a potential therapeutic target to restore immune competency in ALD. Strategies 
aimed at restoring the gut barrier, at functional reprogramming of MAIT cells or the use of MAIT cells derived from induced pluripotent 
stem cells (iPSC-derived MAIT cells) may represent novel attractive immunotherapeutic avenues to allow reconstitution of antibacterial 
immunity.
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(Pierce/Thermo Fisher Scientific, Paisley, UK) and a colorimetric 
D-lactate assay (AbCam, Cambridge, UK) respectively.
Preparation of fixed escherichia coli and faecal extracts of 
bacterial antigens, toxins and metabolites (Feb)
Stocks of E. coli DH5α were grown in RPMI 1640 medium 
(Gibco/Thermo Fisher Scientific), fixed in BD Cytofix buffer 
(formaldehyde 4% in PBS, BD Biosciences, Oxford, UK) (10 min, 
room temperature (RT)), extensively washed in PBS (Gibco/
Thermo Fisher Scientific) and preserved at 4°C–8°C (or −80°C 
for long-term storage). Stool samples from patients with ALD 
and HC were homogenised in PBS. Suspensions were clarified 
with five rounds of centrifugation at increasing speed (1000–
1500 rcf) and duration (1–5 min) to discard debris pellets. Clari-
fied faecal extracts were pelleted, fixed and preserved following 
the same protocol used for E. coli. All bacterial concentrations 
were determined by visual counting with a Neubauer-Petroff 
chamber.
experimental design and cell cultures
Cryopreserved PBMCs were defrosted, counted and used for 
flow cytometry directly or after overnight culture (37°C, 5% 
CO2) in round-bottom 96-well plates (300 000/200 µL/well) 
in RPMI 1640 medium, 10% pooled heat-inactivated human 
AB serum (Sigma-Aldrich), 100 IU/mL penicillin/streptomycin, 
2.2 mmol/L l-Glutamine, 23 mmol/L HEPES (all from Gibco/
Thermo Fisher Scientific). Cell recovery and viability were 
always greater than 90%. Cells were unstimulated or stimulated 
overnight with fixed E. coli (100 bacteria per cell (BpC)). One 
hour before adding E. coli, some cultures were (1) preblocked 
with polyclonal blocking antibody anti-PD1 (10 µg/mL, AF1086, 
BioTechne/R&D Systems, Abingdon, UK); (2) preincubated with 
ARC/SAH plasma (10%); (3) pretreated with increasing concen-
trations of ethanol (50–100–250 mmol/L); or (4) preincubated 
with ARC/SAH/HC faecal extracts (FEB, 100 BpC). Brefeldin A 
(Sigma-Aldrich) was added to cultures used for intracellular flow 
cytometry 1 hour after E. coli (10 µg/mL).
Immunophenotyping, intracellular staining and functional 
apoptosis
MAIT cells were identified by flow cytometry using the following 
panel: CD3/CD4/CD8/TCR_Vα7.2/CD161. We measured (1) 
activation markers and immune checkpoint receptors (CD69/
HLA-DR/PD1/TIM3/LAG3); (2) intracellular cytokines/cytotox-
icity markers (IFNγ/TNFα/IL-17/GranzymeB/Perforin/CD107a); 
(3) homing-related markers (beta7-integrin/CCR9/CXCR3/
CX3CR1/CD26); (4) cytokine receptors (IL-7R/IL-18R); (5) 
proliferation/senescence markers (Ki67/CD57); and (6) tran-
scription factors (RORγt/PLZF/Eomes/T-bet). The impact of 
stool on MAIT cell caspase-dependent apoptosis was assessed by 
exposing healthy PBMC cultures with FEB (as described above) 
and measuring apoptosis rates using the Vybrant-FAM Poly-
Caspase kit (Thermo Fisher Scientific) following the manufac-
turer’s instructions. Online supplementary methods and online 
supplementary table 1 describe the  detailed staining procedure 
and list all the antibodies used. Samples were acquired and anal-
ysed on a FACSCanto-II (BD Biosciences). Levels of expression 
of all markers of interest were measured both as percentage (%) 
of positive cells and as median fluorescence intensity (MFI).
detection of TCr_Vα7.2 (TrAV1-2) by TaqMan PCr
RNA from PBMC and colon pinch biopsies was extracted in 
TriReagent (Ambion/Thermo Fisher Scientific) and chloroform 
(Sigma-Aldrich) (15 min, RT) followed by isopropanol precip-
itation (Sigma-Aldrich) (10 min, RT), washed with ethanol 
(Sigma-Aldrich) 75% in RNAse-free water (Ambion/Thermo 
Fisher Scientific), resuspended in RNAse-free water and stored 
at −80°C. RNA was quantified by NanoDrop spectrophotom-
etry (Thermo Fisher Scientific). cDNA was transcribed with 
QuantiTect Reverse Transcription kits (Qiagen, Manchester, 
UK). Real-time TaqMan PCR was performed on an ABI 7500 
system (Applied Biosystems/Thermo Fisher Scientific) using 
previously published primers and probe.28 29 Online supplemen-
tary methods describe the detailed TaqMan PCR protocol.
Gene expression profiling
Public microarray datasets (Gene Expression Omnibus dataset 
GDS4389, series GSE28619)30 were interrogated to measure 
selected genes of interest in liver tissue from SAH (n=15) and 
healthy controls (n=7). See online supplementary table 2 for the 
lists of all queried/analysed genes.
Identification of TCr_Vα7.2-expressing cells via 
immunohistochemistry and imaging
Immunohistochemistry was performed as previously reported.8 
In brief, cubes of liver tissue (1–1.5 cm3) were cut, snap frozen in 
liquid nitrogen and stored at −80°C. Tissue was then embedded 
in Cryoembed (Leica Biosystems, Newcastle upon Tyne, UK). 
Seven micrometre thick sections were cut using a cryostat 
(specimen temperature: −13°C; chamber: −20°C) and stained 
with purified primary antibody anti-TCR_Vα7.2 (clone 3C10, 
BioLegend, London, UK) or IgG1-isotype-control (1 hour, both 
at 50 µg/mL in PBS) followed by Impress secondary reagent 
(Vector Laboratories, Peterborough, UK) (30 min, RT). Paren-
chyma and portal tracts were imaged on a Zeiss Axioskop 40 
Microscope with 20–40× magnifications and measured using 
AxioVision SE64 V.4.9. Numbers of TCR_Vα7.2(+) cells/mm2 
were counted. Online supplementary methods describe the 
detailed staining procedure.
statistical analyses
Sample size/power calculations (alpha=0.05, beta=0.20) indi-
cated that the numbers of patients used for the main analyses 
were sufficient to evaluate the main differences. Statistical signif-
icance and family-wise alpha for multiple comparisons were set 
at p=0.05. We used (1) Mann-Whitney and Kruskal-Wallis tests 
with Dunn’s multiple comparisons correction for independent 
samples; (2) paired Wilcoxon test for paired samples; (3) χ2 test 
for categorical variables; and (4) Spearman’s rho (ρ) or Pearson’s 
r coefficients for correlations as appropriate. E. coli stimulation 
or pretreatment with patient plasma/ethanol/faecal extracts were 
evaluated by absolute delta change or fold change versus unstim-
ulated or untreated samples as appropriate. Statistics were calcu-
lated with Microsoft Excel, SPSS V.21 and GraphPad Prism.
resulTs
Patient characteristics
All baseline clinical characteristics are summarised in table 1. 
As expected, SAH patients were significantly sicker than ARC 
and had greater propensity to bacterial infection within 1 year 
of recruitment (OR 2.92, 95% CI 0.41 to 20.90): approximately 
half of SAH developed bacterial infection (5/11) compared with 
only a fifth of ARC (2/9). One-third of patients with SAH died 
within 6 months of recruitment, whereas no ARC patients died 
during the study period.
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Marked selective depletion of blood MAIT cells with 
intrahepatic MAIT cell preservation in Ald
MAIT cells were identified as TCR_Vα7.2(+)/CD161(hi) within 
the CD8 T cell population11 (figure 1A). Blood MAIT cells were 
significantly reduced in ARC patients compared with controls 
(p=0.013) and even more dramatically in SAH (p<0.0001) 
(figure 1B). Interestingly, other TCR_Vα7.2(+) T cells28 
were not depleted, and there was no proportional increase of 
CD161(−) CD8 T cells, suggesting this effect was specific to 
MAIT cells and not due to CD161 downregulation (figure 1C).
To investigate the mechanisms inducing MAIT cell depletion 
in ALD, we cultured control/ALD PBMC with fixed E. coli (100 
BpC) and also control PBMC with ALD/control plasma; ALD 
plasma contained significantly higher levels of bacterial products 
than controls (online supplementary figure 1). We found that 
none of these challenges induced MAIT cell deletion (figure 1D). 
We did, however, identify a trend for an association between 
increasing plasma levels of D-lactate (a surrogate marker of 
gut permeability and intestinal translocation) and reduced 
blood MAIT cell frequencies in patients with ALD overall 
(online supplementary figure 1). Additionally, exposing control 
PBMC to ethanol in vitro (50–100–250 mmol/L) had no direct 
MAIT cell toxicity (figure 1E), and ethanol withdrawal in vivo 
did not induce quantitative MAIT cell recovery in excess alcohol 
users undergoing short-term abstinence (online supplementary 
figure 2).
We hypothesised that the observed depletion of blood 
MAIT cells may be due to liver relocation and to assess this 
Figure 1 Blood MAIT cell depletion in patients with ALD. (A) Gating strategy to identify MAIT cells by FACS. (B) Blood MAIT cell frequencies in 
controls (n=13), ARC (n=9) and SAH (n=13) patients. (C) MAIT cell depletion is selective, as TCR_Vα7.2(+) GEM cells and TCR_Vα7.2(+)/CD161(−) 
are unchanged (counts as above). (D) No MAIT cell depletion in healthy PBMC treated with control/ALD plasma (ARC: n=5; SAH: n=5) or blood 
MAIT cells from controls (n=9), ARC (n=9) and SAH (n=9) stimulated with high bacterial load. (E) Lack of MAIT cell depletion upon in vitro ethanol 
treatment of healthy PBMC. ALD, alcohol-related liver disease; ARC, alcohol-related cirrhosis; FACS, flow cytometry; GEM, germline-encoded mycolyl 
lipid-reactive T cells; MAIT, mucosa-associated invariant T cells; PBMC, peripheral blood mononuclear cells; SAH, severe alcoholic hepatitis.
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we evaluated the expression of liver homing markers on blood 
MAIT cells and intrahepatically. We found comparable expres-
sion of these markers (total beta7-integrin, CXCR3, CCR9 and 
CX3CR1) on blood MAIT cells between ALD and controls, and 
blood MAIT cells from all groups always expressed high levels of 
IL-7R, IL-18R and CD26/DPP4 as expected13 31  (online supple-
mentary figure 3). Conversely, microarray data revealed that 
intrahepatic alpha4/alphaE integrins (individual beta7-integrins, 
p<0.02) and also T cell chemoattractant CXCL10 (CXCR3-li-
gand, p<0.001) were hyperexpressed in SAH liver tissue 
compared with controls (figure 2A). Notably, MR1 expression, 
inducible upon bacterial exposure and relevant to MAIT cell 
engagement and killing of infected MR1-expressing cells, was also 
considerably stronger in SAH liver tissue (p<0.002) (figure 2B). 
Taken together these data reveal that there are homing signals in 
the liver that may facilitate intrahepatic MAIT cell relocation or 
retention in ALD.
We then enumerated TCR_Vα7.2(+) cells in fresh-frozen 
liver sections from ARC and healthy liver donors and in colon 
pinch biopsies from ARC patients and controls. Absolute 
Figure 2 Preservation of MAIT cells in the liver in ALD. Intrahepatic hyperexpression of homing markers (A) and MR1 (B) within total liver tissue, 
public microarray dataset analysis (Ctrl: n=7; SAH: n=15). (C) Liver parenchymal and portal TCR_Vα7.2 (clone 3C10) immunohistochemistry to identify 
intrahepatic TCR_Vα7.2(+) cells; fresh-frozen biopsies from ALD livers (n=5) and healthy liver donors (n=5). ALD, alcohol-related liver disease; MAIT, 
mucosa-associated invariant T cells; MR1, MHC-related molecule 1; SAH, severe alcoholic hepatitis.
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numbers of intrahepatic TCR_Vα7.2(+) cells in liver paren-
chymal or portal regions were comparable between patients and 
controls, with similar greater portal accumulation in both groups 
(p=0.008) (figure 2c). TaqMan PCR failed to detect TCR_
Vα7.2/TRAV1-2 transcripts in colon pinch biopsies (but not in 
PBMC, used as a positive control) (data not shown), suggesting 
that MAIT cells may distribute preferentially in locations other 
than the colonic mucosa.
These data show that MAIT cells are not deleted in the liver 
of patients with ALD, although being dramatically depleted in 
their peripheral blood.
blood MAIT cells are phenotypically hyperactivated but 
functionally deficient in Ald
Compounding their significant depletion in the systemic circula-
tion, the remaining population of blood MAIT cells in patients 
with ALD had a marked hyperexpression of canonical activa-
tion markers (CD69: p<0.008; HLA-DR: p<0.03) (figure 3A). 
A comparable hyperactivated status was induced by treating 
control PBMC with ALD plasma (p<0.008) (figure 3B), but not 
with increasing concentrations of ethanol in vitro (figure 3C). 
CD69 can suppress T cell functions through binding with 
its putative ligand Galectin 1 (Gal1),32–34 and we found that 
Gal1 expression was stronger in SAH liver tissue than controls 
(p<0.001) (figure 3D), suggesting greater ability of CD69-medi-
ated intrahepatic MAIT cell inhibition in these patients.
We then assessed whether MAIT cells exhibited signs of 
exhaustion and immune senescence and found no evidence 
of this phenotype in ALD: expression of immune checkpoint 
receptors (PD1/TIM3/LAG3) on blood MAIT cells was compa-
rable in patients and controls (figure 3E); culture of MAIT cells 
with anti-PD1 antibodies did not modulate MAIT cell pheno-
type or function (data not shown); furthermore, proliferation 
or senescence markers (Ki67/CD57) were comparable on blood 
MAIT cells in all subjects (figure 3F).
We next measured MAIT cell antibacterial cytokine produc-
tion (IFNγ/TNFα/IL-17) and cytotoxic capabilities (GranzymeB/
CD107a/Perforin) in response to E. coli challenge. Starting 
from very low cytokine production in basal/unstimulated condi-
tions (figure 4A–C), E. coli stimulation induced similar levels 
of MAIT-specific IFNγ and TNFα in all groups (p<0.008) 
(figure 4A,B), but IL-17-producing MAIT cells were only found 
in controls: ARC patients had a weaker IL-17 response and this 
was completely absent in SAH (p=0.013) (figure 4C).
With regards to cytotoxic potential, MAIT cells from all 
three groups expressed quantifiable basal levels of GranzymeB, 
CD107a and Perforin, which were marginally greater in ALD 
patients (both ARC and SAH) than controls (figure 4D–F). Upon 
E. coli challenge, GranzymeB(+) MAIT cells increased signifi-
cantly only in controls (p=0.004). GranzymeB induction was 
weaker in ARC (p=0.065) and virtually absent in SAH (p=0.002) 
compared with controls (figure 4D). The magnitude of Gran-
zymeB responses correlated directly with blood MAIT cell 
frequencies (ρ=0.673, p<0.001) and inversely with MAIT cell 
expression of activation markers overall (MAIT/CD69_MFI: 
ρ=−0.426, p=0.048; MAIT/HLA-DR%: ρ=−0.558, p=0.007; 
MAIT/HLA-DR_MFI: ρ=−0.523, p=0.012). E. coli-responsive 
CD107a(+) MAIT cells increased significantly in all subjects 
(p<0.016), but the magnitude of this induction was reduced 
in both ARC (p=0.061) and SAH (p=0.034) compared with 
controls (figure 4E). Perforin(+) MAIT cells changed compa-
rably in all subjects in response to E. coli (figure 4F). In few 
patients with SAH, we observed a possible trend for a correlation 
between E. coli-stimulated cytotoxic potential of MAIT cells and 
increased plasma markers of bacterial translocation (CD107a 
induction vs D-lactate in SAH: r=0.985, p=0.015).
MAIT cells have defective expression of innate-like/type-17 
transcription factors in Ald
Innate-like features and functions by MAIT cells require the 
expression of transcription factors RORC/RORγt, ZBTB16/
PLZF, Eomes and T-bet.
We found that expression of RORC/RORγt and ZBTB16/PLZF 
was weaker (MFI) and rarer (% frequency) in blood MAIT cells 
from patients with ALD, particularly in SAH (p<0.006) 
(figures 5A and online supplementary figure 4). MAIT cells 
from SAH also expressed less Eomes and T-bet, although not 
significantly (online supplementary figures 4–5). These results 
paralleled the dramatic depletion of blood MAIT cells and the 
functional defects (IL-17/GranzymeB/CD107a) observed in the 
remaining blood MAIT cells in patients with ARC/SAH. Notably, 
microarray data from SAH liver tissue also showed similar 
features as those observed in blood MAIT cells, with reduc-
tion of RORC/RORγt (p<0.001), ZBTB16/PLZF (p=0.039) 
and also Eomes (p<0.001) compared with healthy liver tissue 
(figure 5B).
Feb alter MAIT cell frequencies, phenotype and functions
Plasma endotoxin and D-lactate were elevated in our patients with 
ALD, confirming increased intestinal permeability and endotox-
emia in these groups (online supplementary figure 1). To test the 
impact of increased bacterial translocation on MAIT cells, we 
treated control PBMC with FEB from ALD patients and controls 
and measured MAIT cell frequency, phenotype and function in 
basal and E. coli-stimulated samples.
Exposure to FEB from ALD stool extracts induced MAIT cell 
depletion compared with untreated samples (p<0.001) and also 
compared with HC stools (p<0.025) (figure 6A). This depletion 
was specific for MAIT cells, as total CD8(+) and total CD3(+) 
cells were not reduced upon exposure (online supplementary 
figure 6). Functional  apoptosis measured by caspase activation 
in MAIT cells was always minimal and comparably low in in all 
stool groups and medium alone (figure 6A).
Expression of MAIT cell activation markers CD69 and 
HLA-DR was approximately 1.5-fold stronger and more 
frequent in samples treated with FEB compared with medium 
alone (p<0.016) (figure 6B). Compared with controls, induc-
tion of CD69 was weaker with FEB from patients with ALD 
but HLA-DR induction was stronger (figure 6B). Exposure to 
FEB also suppressed MAIT cell antibacterial cytokine responses: 
E. coli-responsive MAIT cells producing IFNγ, TNFα or IL-17 
were less frequent with ARC or SAH extracts (but not control) 
(p<0.012) (figure 6C).
FEB also had a significant impact on the cytotoxic capacity of 
MAIT cells, with 50% reduction of GranzymeB(+) MAIT cell 
frequency (p<0.008) and 30%–60% drop in intracellular 
granule content (MFI) (p<0.008). This effect was stronger with 
SAH extracts (figure 6D). Perforin content was also reduced by 
approximately 10% in healthy MAIT cells upon FEB exposure 
(p<0.01) (figure 6D), while CD107a expression and responses 
to E. coli were unaffected by FEB (figure 6D).
dIsCussIon
Our work describes for the first time the characterisation of 
MAIT cell dysfunctions in the immunopathogenesis of ALD. We 
reveal a broad spectrum of dramatic quantitative and functional 
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impairments, both in patients with ARC and particularly in 
those with SAH, possibly signifying an association with disease 
severity.
We also show for the first time that intestinal bacterial anti-
gens and metabolites drive selective MAIT cell depletion (not 
affecting CD8/CD3 T cells) and impair MAIT cell antibacterial 
functionality. This suggests that in patients with ALD, where loss 
of gut integrity is well characterised,35 36 the increased translo-
cation of gut bacteria, bacterial antigens and metabolites could 
be detrimental to gut MAIT cells locally and result in systemic 
depletion of blood MAIT cells and decreased antimicrobial effi-
cacy in the remaining circulating population. In fact, MAIT cell 
alterations have also been described in other conditions including 
inflammatory bowel disease (IBD), obesity and diabetes7 9 10 
known to harbour gut barrier defects and increased intestinal 
permeability. While faecal extracts from both ALD patients and 
controls had effects on MAIT cells overall, there was a greater 
functional impact from patients with ALD. This may be due to the 
Figure 3 Blood MAIT cells in ALD display a hyperactivated phenotype. (A) CD69/HLA-DR hyperexpression by ALD blood MAIT cells compared 
with controls (n=9 for all groups). (B) ALD plasma (ARC plasma: n=5; SAH plasma: n=5) can increase CD69/HLA-DR expression in healthy PBMC 
compared with control plasma. (C) MAIT cell activation status is not induced by in vitro ethanol treatment of healthy PBMC. (D) Gal1 expression is 
increased in SAH liver tissue (control: n=7; SAH: n=15), public microarray dataset analysis. (E) Immunoinhibitory checkpoints are not upregulated 
on hyperactivated blood MAIT cells in ALD (n=9 for all groups). (F) Comparable levels of cell proliferation/senescence markers (Ki67/CD57) between 
groups (n=5 for all groups). ALD, alcohol-related liver disease; ARC, alcohol-related cirrhosis; Gal1, Galectin 1; MAIT, mucosa-associated invariant T 
cells; PBMC, peripheral blood mononuclear cells; SAH, severe alcoholic hepatitis. 
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known bacterial dysbiosis observed in patients with ALD.3 37 38 
Physiologically, the intestinal wall is intact, acting as a defensive 
barrier against the penetration of bacterial products,35 36 and 
mesenteric clearance of translocated bacteria and products is 
effective.39 Conversely, the breakdown of the intestinal barrier 
in ALD further drives the translocation of macromolecules, 
microbial products and microbiota,40 and the loss of mesenteric 
bacterial clearance facilitates direct contact with immunocytes.39 
Moreover, in ALD, it is well described that dysbiosis and micro-
biota composition are further detrimental to gut barrier integrity 
due to the increased production of toxic bacterial metabolites 
such as phenolic compounds, which increase inflammation and 
directly drive intestinal permeability.38
Several other mechanisms could also have been responsible 
for the observed MAIT cell depletion during ALD, including 
direct ethanol toxicity or loss of detection due to activation-re-
lated CD161 downregulation.41 We excluded these hypotheses 
experimentally and our data suggest that MAIT cell depletion is 
a direct consequence of contact with gut bacteria, bacterial anti-
gens and metabolites due to loss of gut integrity and increased 
gut permeability as likelier pathogenic mechanisms, possibly 
through activation-induced cell death.42 Our investigation 
excludes caspase-dependent apoptosis as the driving cause of 
MAIT cell loss in our study and we believe that other pathways 
of both programmed and accidental caspase-independent cell 
death may be at play such as autophagy, necroptosis, pyroptosis 
or necrosis.43 The processes by which MAIT cells die have not 
been fully elucidated in the literature and this does require more 
in-depth investigations.
It has been suggested that recent excess drinking may cause a 
significant decrease in circulating lymphocyte levels in alcohol 
users compared with those without recent drinking.44 As all the 
patients in the current study were actively drinking, this could 
be a contributing factor to the observed MAIT cell reduction. To 
investigate this, we evaluated MAIT cell frequencies in a cohort 
of long-term heavy actively drinking alcohol abusers undergoing 
monitored short-term alcohol withdrawal at baseline, when 
they were actively drinking, and after 2–5 days of monitored 
alcohol abstinence and we observed no changes in MAIT cell 
levels. While these results give further support to our conclusion 
that ethanol does not impact MAIT cell frequencies, they do not 
directly address the possibility that recent and excessive drinking 
Figure 4 Blood MAIT cells show defective antibacterial cytokine/cytotoxic responses in ALD. (A)–(C) MAIT-specific IFNγ, TNFα and IL-17 responses 
upon in vitro Escherichia coli stimulation of ALD/control PBMC, absolute frequencies, and Δ-changes versus unstimulated samples. (D)–(F) MAIT cell 
GranzymeB, CD107a and Perforin responses upon in vitro E. coli stimulation of ALD/control PBMC; absolute frequencies and fold-changes versus 
unstimulated samples (n=9 for all groups). ALD, alcohol-related liver disease; ARC, alcohol-related cirrhosis; IFN, interferon; IL, interleukin; MAIT, 
mucosa-associated invariant T cells; PBMC, peripheral blood mononuclear cells; SAH, severe alcoholic hepatitis; TNF, tumour necrosis factor.
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(especially in patients with SAH) causes MAIT cell depletion. 
We believe that further studies are needed to clarify whether 
long-term abstinence can improve MAIT cell alterations in ALD, 
possibly via restoration of gut integrity. Leclercq et al,38 showed 
that 3 weeks of alcohol abstinence can reduce (but not elimi-
nate) gut permeability in patients with ALD, and this is relevant 
when considering that even long-term abstinence only partially 
restores immunity in ALD38 45 and vulnerability to infection still 
remains in some of these patients.45
We found that intrahepatic MAIT cells in ALD were not deleted, 
in spite of blood MAIT cell depletion. Moreover, beta7-integrins 
and chemoattractant CXCL10 were increased in SAH liver tissue 
compared with controls, suggesting stronger T cell recruitment 
potential in these patients. Intrahepatic MAIT cells showed pref-
erential portal accumulation, and we also observed that SAH 
liver tissue strongly expressed MR1 compared with controls, 
suggesting greater potential of MAIT cell TCR engagement 
in these patients. MAIT cell preservation in peripheral tissues 
despite blood depletion has been previously described,8 23 42 46 
and Jeffery et al8 showed that intrahepatic MAIT cells express 
more gut homing beta7-integrins and CXCR3 than blood 
MAIT cells and more CXCR3 in patients compared with 
controls. Liver and gut acquire similar homing receptor profiles 
in pathological conditions,47 possibly allowing redistribution of 
immunocytes including MAIT cells during pathological inflam-
mation following gradients of physiological chemoattractants 
such as CXCL10, which are upregulated in many types of 
inflammation and in chronic liver diseases regardless of aeti-
ology.48 49 We believe that several cell subsets are recruited to 
the inflamed liver in patients with ALD, that MAIT cells may 
participate to this same enterohepatic recirculation and that 
consequently they can be at least numerically maintained in ALD 
livers although being deleted in the peripheral blood. MAIT cell 
portal accumulation has been suggested as indicative of their 
key role as biliary firewall protecting the epithelial lining from 
translocated bacteria,8 and the observed MR1 upregulation 
would seem to further support this, as it is known to occur upon 
bacterial uptake,16 which is likely increased in patients with 
increased gut permeability. Intrahepatic MAIT cell preservation 
and increased MR1 expression in ALD livers may also favour 
intensified MAIT-mediated tissue damage, as MAIT cells can kill 
MR1-expressing cells.8 11 20–24 Notably, not only did we observe 
higher basal expression of MAIT cell cytotoxicity markers in 
ALD than controls, but among ALD patients we also observed 
a small trend for stronger bacteria-induced MAIT cell cytotox-
icity in those with increased plasma markers of bacterial trans-
location. Microarray dataset results are generally not limited 
to a single cell type only but extend to the investigated tissue/
organ as a whole. For this reason, we believe that further studies 
are required to clarify the migration patterns and expression of 
homing receptors on blood, gut and liver MAIT cells specifically, 
in the context of alcoholic liver disease.
We did not detect MAIT-specific TCR_Vα7.2/TRAV1-2 tran-
scripts in colon pinch biopsies of patients with ARC. The diffi-
culty of obtaining both hepatic and intestinal tissue in patients 
with ALD, due to the issues of deranged coagulation and signif-
icant ascites that are found in many of these patients, precluded 
the in-depth analysis of intestinal MAIT cells, in particular in 
patients with SAH. We cannot exclude extrahepatic accumula-
tion of MAIT cells in the mesenteric lymph nodes, where leaked 
bacterial products and bacteria-loaded mucosal antigen-pre-
senting cells are likely to concentrate prior to systemic distribu-
tion.35 36 39 40
MAIT cells from patients with ALD exhibited significantly 
compromised antibacterial cytokine and cytotoxic functions 
particularly with loss of IL-17, which plays an essential role in 
controlling bacterial dissemination and actively initiating the 
antibacterial response cascade.50 Loss of this function could 
incapacitate localised and systemic host immunity to bacte-
rial infection and is especially relevant to E. coli infection, 
which is one of the most common bacterial species found in 
cirrhotics.2 3
Transcription factors including RORγt, PLZF, Eomes and 
T-bet are strongly expressed in healthy MAIT cells51 and drive 
the acquisition of their innate-like/type-17 functional features, 
including mucosal and liver homing.52–55 The loss of antibac-
terial activity in our patients was found to be associated with 
loss of these transcription factors (RORγt and PLZF). Analogous 
findings were reported in HIV,51 and we hypothesise various 
mechanisms for this dysfunctional profile in ALD.
First, it is known that in vitro long-term bacterial stimula-
tion can suppress MAIT cell expression of RORγt and PLZF,51 
suggesting that strong/chronic exposure to microbial antigens 
in pathological conditions in vivo could be responsible for this 
phenomenon, driving MAIT cells into ‘poised/stunted’ activa-
tion. This corresponds to our observations in ALD, which were 
always more pronounced in patients with more severe disease, 
Figure 5 Defective expression of innate-like/type-17 transcription 
factors by blood MAIT cells and intrahepatically in ALD. (A) Blood 
MAIT cells from ALD display reduced expression of RORC and PLZF 
compared with controls (n=5 for all groups). (B) SAH liver tissue (n=15) 
underexpresses RORC, PLZF and Eomesodermin compared with healthy 
liver tissue (n=7). ALD, alcohol-related liver disease; ARC, alcohol-
related cirrhosis; MAIT, mucosa-associated invariant T cells; SAH, severe 
alcoholic hepatitis.
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Figure 6 Contact between healthy PBMC and faecal extracts of bacterial antigens, toxins and metabolites (FEB) from ALD patients and controls 
causes quantitative and functional impairments of MAIT. (A) FEB-induced MAIT cell depletion. Apoptosis rates are not different between the groups, 
illustrating that FEB-induced MAIT cell depletion is apoptosis independent. Control stools: n=12; ARC stools: n=20; SAH stools: n=7. The bar plot 
represents mean±SD. The black bars represent % of apoptotic VybrantFAM(+) MAIT cells; the white/shaded bars represent MAIT cell frequencies; 
both quantities are measured on the total CD8 T cell population, as described in ‘Materials and Methods’. (B) FEB-induced hyperactivated state on 
MAIT, CD69/HLA-DR. (C) FEB-induced immunoinhibitory checkpoint upregulation, PD1/TIM3/LAG3. FEB-induced suppression of MAIT cell antibacterial 
cytokine (D) and cytotoxic (E) responses; zebra bars represent Escherichia coli-stimulated results. In panels B–E, control stools: n=8; ARC stools: n=18; 
SAH stools: n=5. ALD, alcohol-related liver disease; ARC, alcohol-related cirrhosis; MAIT, mucosa-associated invariant T cells; PMBC, peripheral blood 
mononuclear cells; SAH, severe alcoholic hepatitis.
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where plasma concentrations of markers of bacterial transloca-
tion and dissemination were higher.
Second, blood MAIT cells in our patients with ALD displayed 
increased CD69 expression, in line with published literature.7–11 
Raised CD69 expression on MAIT cells could be linked to 
encountering gut bacteria33 and is relevant for lymphocyte 
enterohepatic recirculation,8 23 33 with likelier hyperexpres-
sion on MAIT cells from ALD than controls, as contact with 
gut bacteria may be more substantial in patients with increased 
gut leakiness. Furthermore, CD69 hyperexpression is known 
to render T cells more susceptible to CD69:Gal1-mediated 
suppression of innate-like/type-17 transcription factors and 
responses.32–34 Notably, in our analysis, Gal1 expression was 
significantly higher in SAH liver tissue than controls, and it has 
been shown that intrahepatic MAIT cells express increased levels 
of CD69 in a diverse range of liver diseases.8
Lastly, it is known that adult MAIT cells are partially unre-
sponsive to TCR-dependent stimulation without secondary cyto-
kine signals, thus undergoing ‘poised’ functional activation.56 
One of the most potent MAIT-stimulating cytokines, IL-7, 
induced MAIT cell functional restoration in HIV,51 reactivating 
MAIT cell proliferation and cytokine production, including 
IL-17.14 51 IL-7 is relevant to liver disease, being one of the 
first and strongest cytokines produced by hepatocytes during 
liver inflammation.57 However, in our study, blood MAIT cells 
expressed IL-7R (CD127) regardless of disease status, suggesting 
IL-7 as potential novel immunotherapeutic target for MAIT cell 
functional rescue in ALD. IL-15 is also known to enhance 
MAIT cell activity, although less powerfully.56 58 59 Whether this 
difference may be therapeutically advantageous requires further 
study, but reprogramming MAIT cells with IL-15 could boost 
their antibacterial activities while potentially avoiding maximal 
activation and overwhelming MAIT-mediated tissue damage.
In our study, patients with SAH had the strongest MAIT cell 
loss and dysfunction and a greater frequency of acquired bacte-
rial infection compared with ARC. The susceptibility to bacterial 
infection in our patients was also potentially underestimated, 
as most SAH were treated prophylactically with antibiotics on 
hospital admission and recruitment. This association is also 
supported by studies from Grimaldi et al7, who show that propen-
sity to bacterial infections is inversely correlated to MAIT cell 
counts. We believe that MAIT cell defects may be important for 
the susceptibility to infection observed in ALD, responsible for 
increased morbidity and mortality in these patients.2 3 Further-
more, we believe that MAIT cells provide an important link to 
the intestinal immunity, which has to date remained elusive in 
this disease.
The state of immunoparesis characteristic of patients with 
ALD, especially patients with SAH, may be intensified by the 
combination of quantitative MAIT cell depletion and func-
tional defects associated with the residual MAIT cell popula-
tion. Ex vivo functionally reprogrammed MAIT cells,14 51 MAIT 
cells derived from induced pluripotent stem cells (iPSC-derived 
MAIT cells)60 and strategies aimed at restoring the gut barrier 
may represent novel attractive immunotherapeutic avenues for 
cirrhosis and alcoholic liver disease.
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